Skip to main content


Pressmeddelande   •   Sep 19, 2019 11:26 CEST

New Data Show Clinical Responses in Colorectal and Appendiceal Cancer Patients Treated With AMG 510 

Two Late-Breaking Abstracts With Data Highlighting IMLYGIC® (Talimogene Laherparepvec) for Neoadjuvant Melanoma and in Combination for Advanced Melanoma 

Results From Studies Across Marketed Portfolio in Cancer Patients With Solid Tumors

THOUSAND OAKS, Calif. (Sept. 17, 2019) – Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019.

Clinical data presentations will include a poster discussion on the ongoing Phase 1 trial of AMG 510, highlighting responses in KRAS G12C-mutant solid tumors, including patients with advanced non-small cell lung, colorectal and appendiceal cancers. AMG 510 is the first KRASG12C inhibitor to reach the clinical stage in patients with locally advanced or metastatic KRAS G12C-mutated solid tumors.

Data showing the two-year results of a Phase 2 trial in patients with neoadjuvant melanoma being treated with IMLYGIC ® (talimogene laherparepvec) plus surgery versus immediate surgery will be presented as a late-breaking abstract in an oral presentation. A second late-breaking abstract featuring IMLYGIC will be presented in a poster discussion session, highlighting three-year follow-up data of a Phase 2 trial with IMLYGIC in combination with YERVOY® (ipilimumab) for advanced melanoma.

“The data being presented at ESMO demonstrate how Amgen is advancing the next frontier of innovation in the treatment of cancers,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “In addition to the responses seen in non-small cell lung cancer patients with KRAS G12C-mutant tumors, we will report the first responses in advanced colorectal and appendiceal cancers at the upcoming congress.”

To read the full global press release, please click here.

For prescribing information in Swedish, please visit

About Amgen Oncology

Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we are driven by our commitment to transform the lives of cancer patients and keep them at the center of everything we do.

For more information, follow us on

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on


CONTACT: Amgen, Thousand Oaks

Trish Hawkins, 805-447-5631 (Media)

Jessica Akopyan, 805-447-0974 (Media)

Arvind Sood, 805-447-1060 (Investors)

Amgen Sweden: 

Karin Järperud, VD, 072-2002532

Maria Eriksson Svensson, Medicinsk chef, 076-1099440